ArticleTheranostics2020
A Microfluidic Platform for Single Cell Fluorometric Granzyme B Profiling.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- T-cell activity feedback-guided photothermal immunotherapy enabled by immune-responsive redox nanodots.Materials today. Bio · 2026Article
- From single cell analysis to 3D micro physiological systems: microfluidic tools integrating cancer cell targets for delineating natural killer cell biology.Microsystems & nanoengineering · 2026Review
- High-throughput proliferation and activation of NK-92MI cell spheroids via a homemade one-step closed bioreactor in pseudostatic cultures for immunocellular therapy.Journal of biological engineering · 2024Article
- Defining T cell receptor repertoires using nanovial-based binding and functional screening.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Development of Nano-Micro Fused LSPR Chip for In Situ Single-Cell Secretion Analysis.Micromachines · 2023Article
- A High-Throughput Single-Cell Assay on a Valve-Based Microfluidic Platform Applied to Protein Quantification, Immune Response Monitoring, and Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Microfluidic devices: The application in TME modeling and the potential in immunotherapy optimization.Frontiers in genetics · 2022Review
- Microfluidic systems to study tissue barriers to immunotherapy.Drug delivery and translational research · 2021Article
- The future of microfluidics in immune checkpoint blockade.Cancer gene therapy · 2021Review
- Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages.Cancers · 2021Review
- A design and optimization of a high throughput valve based microfluidic device for single cell compartmentalization and analysis.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granzyme B (GrB) is an essential cytotoxic effector in cancer immunotherapy as it can be a potential biomarker to predict the efficacy of immunotherapies including checkpoint inhibitors. Monitoring the Granzyme B activity in cells would help determine a patient's clinical response to treatment and lead to better treatment strategies by preventing administration of ineffective therapies and avoid adverse events resulting in a delay in subsequent treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.